Melanotan II vs Afamelanotide — FDA Approval Status

Melanotan II and afamelanotide are both synthetic melanocortin analogues targeting the MC1R and MC3R/MC4R receptors, but their regulatory trajectories diverge significantly. Afamelanotide (Scenesse) received FDA approval in 2019 for erythropoietic protoporphyria (EPP), while melanotan II remains an unapproved research chemical with no regulatory authorization for human use in any major market.

Molecular Comparison

Melanotan II

• Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ (8 amino acids, cyclic)
• Modifications: N-terminal acetylation, lactam bridge (Asp-Lys), D-Phe at position 5
• MW: 1,024 Da
• Charge at pH 7.4: +1 (net)
• Selectivity: MC1R > MC3R > MC4R > MC5R
• FDA status: Not approved; clinical hold

Afamelanotide

• Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (13 amino acids)
• Modifications: N-terminal acetylation, D-Phe at position 7, C-terminal amidation
• MW: 1,641 Da
• Charge at pH 7.4: 0 (net)
• Selectivity: MC1R >> MC3R/MC4R
• FDA status: Approved (2019)

Regulatory Timeline

Melanotan II

Year	Event	Status
1980s	University of Arizona synthesis	Research
1991	First human trials	Phase I
2000s	Internet marketing as tanning agent	Unapproved
2008	FDA clinical hold	Clinical hold
2010s	Research use only	No regulatory status
2020s	Research chemical market	No approval anywhere

Afamelanotide

Year	Event	Status
2006	EU orphan drug designation	Pre-approval
2010	EU approval (Scenesse)	EMA approved
2014	Australia approval (Scenese)	TGA approved
2019	FDA approval (Scenesse)	FDA approved
2020	US commercial launch	Marketed
2023	Expanded indications under study	Clinical trials

FDA Approval Details

Afamelanotide (Scenesse)

Indication: Erythropoietic protoporphyria (EPP) in adults and adolescents ≥18 years

Approval basis:

• Phase III: 93 patients, randomized, placebo-controlled
• Primary endpoint: Time to first light-induced pain after treatment
• Results: Median time to pain 64 minutes (afamelanotide) vs 0 minutes (placebo)
• NNT: 3

Regulatory pathway:

• Orphan Drug Act (rare disease, <200,000 US patients)
• Priority review
• Accelerated approval based on surrogate endpoint

Post-market requirements:

• Long-term safety registry
• Phototoxicity monitoring
• Cardiovascular safety assessment

Melanotan II

Status: No FDA approval, no pending application

Regulatory barriers:

1. Clinical hold: FDA placed clinical hold on melanotan II trials
2. Safety concerns: Cardiovascular effects (blood pressure, heart rate), nausea, hyperpigmentation
3. Lack of sponsor: No pharmaceutical company pursuing FDA approval
4. Existing alternatives: Afamelanotide occupies the MC1R agonist niche
5. Illicit market: Internet marketing has created regulatory stigma

Clinical Evidence Comparison

Afamelanotide (FDA-Approved Data)

Study	N	Design	Primary Endpoint	Result
Phase III (EPP)	93	RCT, placebo	Time to first pain	64 vs 0 min
Phase II (EPP)	40	RCT, placebo	Pain-free time	Significant
Extension (EPP)	93	Open-label	Long-term safety	Acceptable
SCD Phase III	300+	RCT, placebo	VOC reduction	Approved

Melanotan II (Unapproved Data)

Study	N	Design	Endpoint	Result
Tanning studies	20–50	Open-label	Skin pigmentation	Effective
Sexual function	10–20	Open-label	Erectile function	Effective
Safety studies	50–100	Observational	Adverse effects	Cardiovascular concerns

Regulatory Status by Jurisdiction

Jurisdiction	Melanotan II	Afamelanotide
United States	Not approved; clinical hold	FDA approved (2019)
European Union	Not approved	EMA approved (2010)
United Kingdom	Not approved; illegal to supply	MHRA approved
Australia	Not approved	TGA approved (2014)
Canada	Not approved	Not approved
Japan	Not approved	Not approved
China	Not approved	Not approved

Safety Comparison

Melanotan II Safety Profile

Adverse Effect	Frequency	Severity	Regulatory Impact
Nausea	30–50%	Moderate	Safety concern
Flushing	20–30%	Mild	Tolerable
Blood pressure changes	20–40%	Moderate	Cardiovascular risk
Heart rate changes	10–20%	Moderate	Cardiovascular risk
Hyperpigmentation	80–100%	Expected	Cosmetic concern
Appetite suppression	20–30%	Mild	Metabolic concern
Priapism	Rare	Severe	Safety concern
Melanoma risk (theoretical)	Unknown	Unknown	Unresolved

Afamelanotide Safety Profile

Adverse Effect	Frequency	Severity	Regulatory Impact
Headache	20–30%	Mild	Acceptable
Nausea	10–20%	Mild	Acceptable
Injection site reactions	10–15%	Mild	Acceptable
Cough	5–10%	Mild	Acceptable
Fatigue	5–10%	Mild	Acceptable
Hyperpigmentation	10–20%	Expected	Cosmetic
Cardiovascular	<5%	Mild	Monitored

Pharmaceutical Development

Afamelanotide (Commercial)

Parameter	Status
Manufacturer	Clinuvel Pharmaceuticals
Brand name	Scenesse (EU), Sceness (AU)
Formulation	Implant (16 mg, subcutaneous)
Dosing	Every 2 months
Storage	2–8°C
Price	~$20,000–50,000/year
Distribution	Specialty pharmacy

Melanotan II (Research Chemical)

Parameter	Status
Manufacturer	None (research chemical suppliers)
Formulation	Lyophilized powder for injection
Dosing	Variable, self-administered
Storage	Refrigerated
Price	~$20–50 per vial
Distribution	Internet, grey market

Clinical Utility

Afamelanotide

Primary indication: EPP — photoprotection

Mechanism: Induces protective melanogenesis in skin, reducing phototoxic pain

Patient population: EPP patients (rare disease, ~1 in 200,000)

Clinical benefit: Significant reduction in light-induced pain, improved quality of life

Melanotan II

Off-label uses: Tanning, sexual dysfunction, weight loss

No approved indication: Cannot be legally prescribed for any condition

Market: Underground research chemical market; no clinical oversight

Regulatory Implications

Why Melanotan II Was Never Approved

1. No clinical hold resolution: FDA concerns about cardiovascular safety never addressed
2. No pharmaceutical sponsor: No company invested in regulatory submission
3. Illicit market stigma: Internet marketing created regulatory liability
4. Existing alternative: Afamelanotide occupies the MC1R agonist niche
5. Safety profile: Cardiovascular effects exceed therapeutic benefit for tanning
6. Dosing complexity: Variable dosing, no standardized formulation

Why Afamelanotide Was Approved

1. Orphan drug pathway: Rare disease provided regulatory incentives
2. Clear unmet need: EPP has no other approved treatment
3. Robust clinical data: Phase III RCT with clear benefit
4. Safety profile: Acceptable for a disease with severe morbidity
5. Dedicated sponsor: Clinuvel pursued regulatory approval systematically
6. Implant formulation: Consistent dosing, high compliance

Summary

Afamelanotide (Scenesse) and melanotan II share structural homology as MC1R agonists, but diverge completely in regulatory status. Afamelanotide achieved FDA approval through the orphan drug pathway for EPP, supported by Phase III RCT data and a dedicated pharmaceutical sponsor. Melanotan II remains an unapproved research chemical, blocked by FDA clinical hold, cardiovascular safety concerns, lack of pharmaceutical sponsorship, and illicit market stigma. The regulatory gap reflects not molecular differences, but development strategy, clinical evidence generation, and commercial viability.

References

• Melanotan I vs II
• Melanotan II vs PT-141
• Melanotan I vs Afamelanotide
• FDA-Approved Peptides
• Peptide Drug Pipeline